Skip to main content
. 2026 Feb 27;11(2):aakag015. doi: 10.1093/esj/aakag015

Table 2.

Outcomes comparison.

Unweighted cohort Weighted cohort
Cancer (n = 247) No cancer (n = 1,402) Cancer (n = 759) No cancer (n = 890) Statistical metric a Weighted difference [95% CI] P value
Primary outcome
90-day new ischaemic stroke or TIA, n (%) 20 (8.1) 37 (2.6) 62 (8.2) 25 (2.8) Adjusted hazard ratio 2.56 [1.59–4.13] <.001
Secondary outcomes
90-day mRS score distribution Adjusted odds ratio 1.29 [1.08–1.54] .005
 No symptoms (score of 0), n (%) 13 (5.3) 172 (12.3) 84 (11.1) 112 (12.6)
 Symptoms without any disability (score of 1), n (%) 33 (13.4) 251 (17.9) 85 (11.2) 163 (18.3)
 Symptoms with mild disability (score of 2), n (%) 36 (14.6) 205 (14.6) 128 (16.9) 150 (16.9)
 Symptoms with mild-to-moderate disability (score of 3), n (%) 48 (19.4) 221 (15.8) 145 (19.1) 140 (15.7)
 Symptoms with moderate-to-severe disability (score of 4), n (%) 42 (17.0) 178 (12.7) 121 (15.9) 110 (12.4)
 Symptoms with severe disability (score of 5), n (%) 19 (7.7) 97 (6.9) 60 (7.9) 57 (6.4)
 Death (score of 6), n (%) 56 (22.7) 278 (19.8) 136 (17.9) 158 (17.8)
90-day all-cause death, n (%) 56 (22.7) 278 (19.8) 136 (17.9) 158 (17.8) Adjusted hazard ratio 0.98 [0.78–1.24] .883
90-day vascular death, n (%) 31 (12.6) 184 (13.1) 82 (10.8) 101 (11.3) Adjusted hazard ratio 0.94 [0.70–1.26] .677
Safety outcomes
90-day moderate-to-severe bleeding, n (%) 16 (6.5) 39 (2.8) 33 (4.3) 21 (2.4) Adjusted hazard ratio 1.82 [1.05–3.14] .033
90-day ICH, n (%) 7 (2.8) 22 (1.6) 16 (2.1) 11 (1.2) Adjusted hazard ratio 1.66 [0.77–3.58] .194
24-h haemorrhagic transformation, n (%) 35 (14.2) 252 (18.0) 125 (16.5) 158 (17.8) Adjusted risk difference (%) 0.2 [−3.8 to 4.2] .931

Global Schoenfeld residual P-values: 90-day new ischaemic stroke or TIA = 0.422; 90-day vascular death = 0.550; 90-day all-cause death = 0.861; 90-day moderate-to-severe bleeding = 0.663; 90-day ICH = 0.224. Statistically significant P-values (<0.05) are reported in bold.

aAdjusted for baseline covariates that remained imbalanced (SMD > 0.10) after weighting (age, ethnicity, pre-stroke mRS, atrial fibrillation type, post-stroke anticoagulation strategy).